Ahmed Telbany
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmed Telbany has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Osama Hamid
Division of Gastroenterology & Hepatology, University of Texas Southwestern, Dallas, Texas, USA
4 shared publicationsGulshan Parasher
Division of Gastroenterology & Hepatology, University of New Mexico, Albuquerque, New Mexico, USA
3 shared publicationsIslam Mohamed
Division of Gastroenterology & Hepatology, University of Missouri, Columbia, Missouri, USA
3 shared publicationsKhaled Alsabbagh Alchirazi
Division of Gastroenterology & Hepatology, Aurora healthcare, Milwaukee, Wisconsin, USA
3 shared publications- Abdelrahman Yousef
Department of Internal Medicine, University of New Mexico, Albuquerque, NM
2 shared publications - Abu Baker Sheikh
Department of Internal Medicine University of New Mexico Albuquerque New Mexico USA
2 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4449
Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth
Background: Rifaximin is widely used in the management of small intestinal bacterial overgrowth (SIBO), but concerns remain regarding the potential risk of Clostridioides difficile infection (CDI), particularly with repeated antibiotic exposure. Aim: To evaluate the short-term risk of CDI following Rifaximin therapy in patients with SIBO. Materials and Methods: We conducted a retrospective cohort study using the TriNetX Collaborative Research Network. Adult patients with SIBO were identified and categorized based on Rifaximin exposure within 60 days of diagnosis. The primary analysis compared patients with SIBO treated with Rifaximin to those with SIBO who did not receive Rifaximin. Secondary analyses included comparisons between SIBO patients treated with Rifaximin and irritable bowel syndrome (IBS) patients receiving Rifaximin, as well as patients with SIBO receiving a single versus multiple Rifaximin courses. Propensity score matching (1:1) was performed to balance baseline characteristics. The primary outcome was CDI within 60 days of the index event. Secondary outcomes included hospitalization and emergency department (ED) visits. Results: After propensity score matching, 19,597 patients were included in each cohort in the primary comparison of SIBO treated with Rifaximin versus SIBO without Rifaximin. CDI occurred in 0.21% of Rifaximin-treated patients and 0.15% of untreated patients (p = 0.152). In the contextual comparison, CDI incidence was similar between SIBO patients receiving Rifaximin and IBS patients receiving Rifaximin (0.21% vs. 0.15%, p = 0.168). Among patients with SIBO receiving Rifaximin, CDI risk did not differ between single and multiple treatment courses (0.20% vs. 0.21%, p = 0.850). Conclusions: In this large real-world cohort, Rifaximin therapy for SIBO was not associated with a statistically significant increase in short-term CDI risk. However, given the low event rate, wide confidence intervals, and risk of type II error, these findings should be interpreted with caution.
- 9 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4449
Open AccessEvaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth
Background: Rifaximin is widely used in the management of small intestinal bacterial overgrowth (SIBO), but concerns remain regarding the potential risk of Clostridioides difficile infection (CDI), particularly with repeated antibiotic exposure. Aim: To evaluate the short-term risk of CDI following Rifaximin therapy in patients with SIBO. Materials and Methods: We conducted a retrospective cohort study using the TriNetX Collaborative Research Network. Adult patients with SIBO were identified and categorized based on Rifaximin exposure within 60 days of diagnosis. The primary analysis compared patients with SIBO treated with Rifaximin to those with SIBO who did not receive Rifaximin. Secondary analyses included comparisons between SIBO patients treated with Rifaximin and irritable bowel syndrome (IBS) patients receiving Rifaximin, as well as patients with SIBO receiving a single versus multiple Rifaximin courses. Propensity score matching (1:1) was performed to balance baseline characteristics. The primary outcome was CDI within 60 days of the index event. Secondary outcomes included hospitalization and emergency department (ED) visits. Results: After propensity score matching, 19,597 patients were included in each cohort in the primary comparison of SIBO treated with Rifaximin versus SIBO without Rifaximin. CDI occurred in 0.21% of Rifaximin-treated patients and 0.15% of untreated patients (p = 0.152). In the contextual comparison, CDI incidence was similar between SIBO patients receiving Rifaximin and IBS patients receiving Rifaximin (0.21% vs. 0.15%, p = 0.168). Among patients with SIBO receiving Rifaximin, CDI risk did not differ between single and multiple treatment courses (0.20% vs. 0.21%, p = 0.850). Conclusions: In this large real-world cohort, Rifaximin therapy for SIBO was not associated with a statistically significant increase in short-term CDI risk. However, given the low event rate, wide confidence intervals, and risk of type II error, these findings should be interpreted with caution.
- Open Access
Safety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis
Introduction: Live attenuated vaccines (LAVs) are generally avoided in patients with inflammatory bowel disease (IBD) receiving immunomodulatory therapy due to concerns about infection risk. However, real-world data evaluating their safety in this population remain limited. We aimed to assess adverse outcomes following LAV administration in IBD patients treated with biologic agents. Methods: We conducted a retrospective cohort study using the TriNetX multi-institutional database. Adults with IBD receiving immunomodulatory therapy were categorized into two cohorts: those who received an LAV and those who did not. Biologic therapies included tumor necrosis factor inhibitors (infliximab, and adalimumab), integrin antagonists (vedolizumab), interleukin (IL)-12/23 inhibitors (ustekinumab), IL-23 inhibitors (risankizumab, and guselkumab), and Janus kinase inhibitors (tofacitinib, and upadacitinib). LAVs included measles–mumps–rubella (MMR), varicella (Varivax), and yellow fever vaccines. Propensity score matching was performed based on age, sex, IBD subtype (Crohn’s disease vs. ulcerative colitis), and biologic class. Patients with outcomes prior to the risk window were excluded. Adverse outcomes within six months included hospitalization, emergency department (ED) visits, fever, rash, and encephalitis. Results: A total of 672 patients were included in each propensity-score-matched cohort. Live attenuated vaccine (LAV) administration was not associated with significantly increased adverse outcomes compared with no LAV exposure during the six-month follow-up period. Hospitalization occurred in 14.9% versus 15.3% of patients, respectively (risk ratio [RR] 0.97; 95% confidence interval [CI] 0.75–1.25; p = 0.819), while emergency department visits occurred in 12.6% vs 11.3% (RR 1.12; 95% CI 0.84–1.50; p = 0.450). There were no significant differences in fever (3.6% vs. 3.3%; RR 1.09; 95% CI 0.62–1.93; p = 0.764) or rash (4.0% vs. 2.7%; RR 1.50; 95% CI 0.83–2.70; p = 0.172). No cases of measles, mumps, rubella, varicella, yellow fever, or encephalitis were identified in either cohort during follow-up. Conclusions: LAVs were not associated with an increased risk of adverse outcomes within one day to six months among IBD patients receiving immunomodulatory therapy. These real-world findings suggest comparable short-term outcomes between the cohorts of patients with IBD receiving biologic or targeted synthetic therapy who met the predefined eligibility criteria including age ≥ 18 years, and vaccination occurring between two weeks and six months after biologic initiation regarding LAV use in patients with IBD receiving biologic agents.
Open AccessSafety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis
Introduction: Live attenuated vaccines (LAVs) are generally avoided in patients with inflammatory bowel disease (IBD) receiving immunomodulatory therapy due to concerns about infection risk. However, real-world data evaluating their safety in this population remain limited. We aimed to assess adverse outcomes following LAV administration in IBD patients treated with biologic agents. Methods: We conducted a retrospective cohort study using the TriNetX multi-institutional database. Adults with IBD receiving immunomodulatory therapy were categorized into two cohorts: those who received an LAV and those who did not. Biologic therapies included tumor necrosis factor inhibitors (infliximab, and adalimumab), integrin antagonists (vedolizumab), interleukin (IL)-12/23 inhibitors (ustekinumab), IL-23 inhibitors (risankizumab, and guselkumab), and Janus kinase inhibitors (tofacitinib, and upadacitinib). LAVs included measles–mumps–rubella (MMR), varicella (Varivax), and yellow fever vaccines. Propensity score matching was performed based on age, sex, IBD subtype (Crohn’s disease vs. ulcerative colitis), and biologic class. Patients with outcomes prior to the risk window were excluded. Adverse outcomes within six months included hospitalization, emergency department (ED) visits, fever, rash, and encephalitis. Results: A total of 672 patients were included in each propensity-score-matched cohort. Live attenuated vaccine (LAV) administration was not associated with significantly increased adverse outcomes compared with no LAV exposure during the six-month follow-up period. Hospitalization occurred in 14.9% versus 15.3% of patients, respectively (risk ratio [RR] 0.97; 95% confidence interval [CI] 0.75–1.25; p = 0.819), while emergency department visits occurred in 12.6% vs 11.3% (RR 1.12; 95% CI 0.84–1.50; p = 0.450). There were no significant differences in fever (3.6% vs. 3.3%; RR 1.09; 95% CI 0.62–1.93; p = 0.764) or rash (4.0% vs. 2.7%; RR 1.50; 95% CI 0.83–2.70; p = 0.172). No cases of measles, mumps, rubella, varicella, yellow fever, or encephalitis were identified in either cohort during follow-up. Conclusions: LAVs were not associated with an increased risk of adverse outcomes within one day to six months among IBD patients receiving immunomodulatory therapy. These real-world findings suggest comparable short-term outcomes between the cohorts of patients with IBD receiving biologic or targeted synthetic therapy who met the predefined eligibility criteria including age ≥ 18 years, and vaccination occurring between two weeks and six months after biologic initiation regarding LAV use in patients with IBD receiving biologic agents.
- Open Access
- 13 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1474
Candida Esophagitis in Patients with Solid Organ Cancers
Candida esophagitis (CE) is the most common fungal infection of the esophagus and an increasingly recognized complication in patients with solid organ malignancies. Once primarily associated with advanced HIV/AIDS and hematologic malignancies, the epidemiology has shifted in the modern era of antiretroviral therapy and intensive cancer treatments. Patients with solid tumors receiving chemotherapy, corticosteroids, broad-spectrum antibiotics, and proton pump inhibitors (PPIs) are at a heightened risk for CE due to synergistic immunosuppressive and mucosal barrier-disrupting effects. Clinically, CE in cancer patients often present with odynophagia, dysphagia, or chest pain, but a considerable proportion of cases are asymptomatic or non-specific, complicating diagnosis and needing a high index of suspicion. Endoscopic evaluation with characteristic white plaques and histopathologic confirmation remains the diagnostic gold standard, as symptoms as oropharyngeal findings are unreliable indicators of esophageal infection. Disease management centers on systemic antifungal therapy. Fluconazole is the first-line treatment, achieving high cure rates, while echinocandins and posaconazole are reserved for refractory cases or non-albicans infections. Prompt therapy is crucial, as untreated CE can lead to malnutrition, interruptions in cancer therapy, and rare but serious complications (e.g., necrotizing esophagitis or perforation). We provide a comprehensive review of the epidemiology, risk factors, clinical manifestations, pathogenesis, diagnosis, and management of CE in solid organ cancer patients. Gaps in knowledge are highlighted, including the need for better non-invasive diagnostics, antifungal resistance surveillance, and tailored prophylactic strategies. A high index of suspicion and early recognition and treatment of CE in oncology patients can improve nutritional status, quality of life, and continuity of cancer care.
- 13 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1474
Open AccessCandida Esophagitis in Patients with Solid Organ Cancers
Candida esophagitis (CE) is the most common fungal infection of the esophagus and an increasingly recognized complication in patients with solid organ malignancies. Once primarily associated with advanced HIV/AIDS and hematologic malignancies, the epidemiology has shifted in the modern era of antiretroviral therapy and intensive cancer treatments. Patients with solid tumors receiving chemotherapy, corticosteroids, broad-spectrum antibiotics, and proton pump inhibitors (PPIs) are at a heightened risk for CE due to synergistic immunosuppressive and mucosal barrier-disrupting effects. Clinically, CE in cancer patients often present with odynophagia, dysphagia, or chest pain, but a considerable proportion of cases are asymptomatic or non-specific, complicating diagnosis and needing a high index of suspicion. Endoscopic evaluation with characteristic white plaques and histopathologic confirmation remains the diagnostic gold standard, as symptoms as oropharyngeal findings are unreliable indicators of esophageal infection. Disease management centers on systemic antifungal therapy. Fluconazole is the first-line treatment, achieving high cure rates, while echinocandins and posaconazole are reserved for refractory cases or non-albicans infections. Prompt therapy is crucial, as untreated CE can lead to malnutrition, interruptions in cancer therapy, and rare but serious complications (e.g., necrotizing esophagitis or perforation). We provide a comprehensive review of the epidemiology, risk factors, clinical manifestations, pathogenesis, diagnosis, and management of CE in solid organ cancer patients. Gaps in knowledge are highlighted, including the need for better non-invasive diagnostics, antifungal resistance surveillance, and tailored prophylactic strategies. A high index of suspicion and early recognition and treatment of CE in oncology patients can improve nutritional status, quality of life, and continuity of cancer care.
- 17 December 2025
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 103 (1) , 193-194
Response
- 20 November 2025
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 102 (6) , 919-920
Response
- 31 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (1) , 171-178
Liver Cleansing Imposters: An Analysis of Popular Online Liver Supplements
INTRODUCTION: The liver supplement market is rapidly expanding, yet the efficacy and safety of these products remain largely unsubstantiated. The aim of this study was to analyze the best-selling liver “cleansing” supplements on Amazon, the leading online retailer in the United States. METHODS: We identified the top 20 liver cleanse supplements on Amazon using specific search criteria. Product composition, marketing claims, customer reviews, sales data, and revenue were analyzed. AMZScout was used for sales analytics and FakeSpot for review authenticity assessment. The most common ingredients were identified, and their scientific evidence evaluated through structured PubMed searches with predefined criteria for evidence quality assessment. RESULTS: The 20 top-selling supplements generated total annual sales of 1,420,584 units with a revenue of $38,783,937. All products claimed to “eliminate toxins” or provide “liver detox/cleanse,” whereas 85% claimed to “enhance liver function.” The average product rating was 4.4 of 5 stars, with review reliability averaging 73% ± 20%. Milk thistle was the most common ingredient (19/20 products), followed by dandelion and turmeric root (13/20 each). Scientific evidence supporting these ingredients' efficacy in liver health was limited and inconclusive. DISCUSSION: This study reveals a thriving market for liver supplements, despite limited scientific evidence supporting their efficacy. The prevalence of bold health claims, high consumer satisfaction, and significant sales highlight the need for more rigorous evaluation and regulation of these products. Healthcare providers should be aware of these trends to better counsel patients on evidence-based approaches to liver health.
- 31 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (1) , 171-178
Liver Cleansing Imposters: An Analysis of Popular Online Liver Supplements
INTRODUCTION: The liver supplement market is rapidly expanding, yet the efficacy and safety of these products remain largely unsubstantiated. The aim of this study was to analyze the best-selling liver “cleansing” supplements on Amazon, the leading online retailer in the United States. METHODS: We identified the top 20 liver cleanse supplements on Amazon using specific search criteria. Product composition, marketing claims, customer reviews, sales data, and revenue were analyzed. AMZScout was used for sales analytics and FakeSpot for review authenticity assessment. The most common ingredients were identified, and their scientific evidence evaluated through structured PubMed searches with predefined criteria for evidence quality assessment. RESULTS: The 20 top-selling supplements generated total annual sales of 1,420,584 units with a revenue of $38,783,937. All products claimed to “eliminate toxins” or provide “liver detox/cleanse,” whereas 85% claimed to “enhance liver function.” The average product rating was 4.4 of 5 stars, with review reliability averaging 73% ± 20%. Milk thistle was the most common ingredient (19/20 products), followed by dandelion and turmeric root (13/20 each). Scientific evidence supporting these ingredients' efficacy in liver health was limited and inconclusive. DISCUSSION: This study reveals a thriving market for liver supplements, despite limited scientific evidence supporting their efficacy. The prevalence of bold health claims, high consumer satisfaction, and significant sales highlight the need for more rigorous evaluation and regulation of these products. Healthcare providers should be aware of these trends to better counsel patients on evidence-based approaches to liver health.
- 9 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (7) , 1442
Evaluating the Use of Augmented Reality in Endoscopy
An abstract is unavailable. This article is available as a PDF only.
- 9 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (7) , 1442
Evaluating the Use of Augmented Reality in Endoscopy
An abstract is unavailable. This article is available as a PDF only.
- 4 October 2024
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 101 (5) , 965-969
Adverse events of the endoscopic over-the-scope clips and cutters: a Manufacturer and User Facility Device Experience database analysis
- 4 October 2024
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 101 (5) , 965-969
Adverse events of the endoscopic over-the-scope clips and cutters: a Manufacturer and User Facility Device Experience database analysis
- 30 July 2024
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 100 (6) , 1117-1119
Submucosal glands during endoscopic submucosal dissection of esophageal adenocarcinoma
- 30 July 2024
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 100 (6) , 1117-1119
Submucosal glands during endoscopic submucosal dissection of esophageal adenocarcinoma
- 5 February 2024
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 59 (5) , 547-552
Maternal, obstetrical, and neonatal outcomes in celiac disease
ObjectivesSome studies have suggested a link between celiac disease (CD) and adverse maternal, obstetrical, and neonatal outcomes. Using a large database, we evaluated the effect of CD on pregnancy outcomes.MethodsWe conducted a retrospective cohort study using the National Inpatient Sample (NIS) of all deliveries from 2015 to 2019 in the United States. Using ICD-10 codes, we identified pregnant patients who had CD and those who did not. A multivariate logistic regression was used to generate odds ratios (ORs) with 95% confidence intervals (CIs) for maternal, obstetrical, and neonatal outcomes.ResultsOf 12,039,222 deliveries between 2015 and 2019, there were 10,555 births in women with CD. Pregnant women with CD were more likely to be white and older compared to those without CD. Pregnant women with CD were significantly more likely to carry a diagnosis of gestational hypertension (OR 1.26; 95% CI 1.04-1.52), preeclampsia (1.28; 1.08-1.53), and severe preeclampsia (1.62; 1.25-2.09). They were less likely to have a full-term uncomplicated delivery (OR 0.11; 95% CI, 0.05-0.20), while being more likely to require device-assisted delivery (1.25; 1.04-1.50) and sustain 3rd or 4th degree vaginal lacerations (1.56; 1.21-2.02). Babies of pregnant women with CD were more likely to be small for gestational age (SGA) (OR 1.29; 95% CI 1.03-1.61).ConclusionsCD in pregnancy appears to be associated with increased adverse maternal, obstetrical, and neonatal outcomes. Clinicians should discuss these increased risks with CD patients who are planning to conceive.
- 5 February 2024
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 59 (5) , 547-552
Maternal, obstetrical, and neonatal outcomes in celiac disease
ObjectivesSome studies have suggested a link between celiac disease (CD) and adverse maternal, obstetrical, and neonatal outcomes. Using a large database, we evaluated the effect of CD on pregnancy outcomes.MethodsWe conducted a retrospective cohort study using the National Inpatient Sample (NIS) of all deliveries from 2015 to 2019 in the United States. Using ICD-10 codes, we identified pregnant patients who had CD and those who did not. A multivariate logistic regression was used to generate odds ratios (ORs) with 95% confidence intervals (CIs) for maternal, obstetrical, and neonatal outcomes.ResultsOf 12,039,222 deliveries between 2015 and 2019, there were 10,555 births in women with CD. Pregnant women with CD were more likely to be white and older compared to those without CD. Pregnant women with CD were significantly more likely to carry a diagnosis of gestational hypertension (OR 1.26; 95% CI 1.04-1.52), preeclampsia (1.28; 1.08-1.53), and severe preeclampsia (1.62; 1.25-2.09). They were less likely to have a full-term uncomplicated delivery (OR 0.11; 95% CI, 0.05-0.20), while being more likely to require device-assisted delivery (1.25; 1.04-1.50) and sustain 3rd or 4th degree vaginal lacerations (1.56; 1.21-2.02). Babies of pregnant women with CD were more likely to be small for gestational age (SGA) (OR 1.29; 95% CI 1.03-1.61).ConclusionsCD in pregnancy appears to be associated with increased adverse maternal, obstetrical, and neonatal outcomes. Clinicians should discuss these increased risks with CD patients who are planning to conceive.